Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

MLA

Sidana, Surbhi, et al. “Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience.” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 10377–79. EBSCOhost, https://doi.org/10.1182/blood-2022-166058.

APA

Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Atrash, S., Khouri, J., Voorhees, P. M., Dima, D., Simmons, G., Kalariya, N., Hovanky, V., Bharadwaj, S., Arai, S., Miklos, D. B., Wagner, C. B., Davis, J., Sborov, D. W., Nishihori, T., … Hansen, D. K. (2022). Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience. Blood, 140(1, Number 1 Supplement 1), 10377–10379. https://doi.org/10.1182/blood-2022-166058

Chicago

Sidana, Surbhi, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher J. Ferreri, Shebli Atrash, Jack Khouri, et al. 2022. “Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience.” Blood 140 (1, Number 1 Supplement 1): 10377–79. doi:10.1182/blood-2022-166058.